Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 121,474 matching trials from the live ClinicalTrials.gov search.

Filters: Completed Clear all

Conditions: Rheumatoid Arthritis
Interventions: Tocilizumab, Placebo, Permitted DMARDs; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 156
States / cities: Birmingham, Alabama • Montgomery, Alabama • Lake Havasu City, Arizona + 135 more

Conditions: Hematopoietic Neoplasms, Hematopoietic Malignancy
Interventions: STEPP Intervention; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Obesity, Pre-hypertension, Hypertension
Interventions: L-citrulline supplementation, Whole Body Vibration Training; Dietary Supplement · Other
Lead sponsor: Florida State University; Other
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab pegol, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 50
States / cities: Huntsville, Alabama • Montgomery, Alabama • Gilbert, Arizona + 47 more

Conditions: Rectal Cancer, Breast Cancer, Lung Cancer
Interventions: Not listed
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 70 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Intraocular Pressure, Glaucoma
Interventions: iCare HOME2 vs iCare IC200; Device
Lead sponsor: Icare Finland Oy; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: PIK3CA-related Overgrowth Spectrum
Interventions: Alpelisib; Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 5 Years to 99 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Anesthesia, Tooth Extraction
Interventions: Midazolam Hydrochloride, Fentanyl, Ketamine, Propofol injection, Nitrous oxide; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 16 Years and older
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Healthy
Interventions: Olomorasib, Fluconazole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Breast Cancer, Ovarian Cancer
Interventions: questionnaire, interview; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 39 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions: Losmapimod oral tablet, Placebo oral tablet; Drug
Lead sponsor: Fulcrum Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 12
States / cities: Irvine, California • Los Angeles, California • Gainesville, Florida + 9 more

Conditions: Anesthesia, Laryngospasm on Emergence
Interventions: Pupillometry; Diagnostic Test
Lead sponsor: University of California, San Francisco; Other
Eligibility: 2 Years to 10 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Oakland, California

Conditions: Sickle Cell Anemia
Interventions: Hydroxyurea; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1984 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes
Interventions: Diabetes Digital Intervention, Generic Digital Intervention; Behavioral
Lead sponsor: Evidation Health; Industry
Eligibility: 18 Years and older
Enrollment: 94,321 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Mateo, California

Conditions: Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
Interventions: NRX-101 Oral Capsule, Lurasidone Oral Capsule, Ketamine Intravenous Infusion, Saline Solution Intravenous Infusion; Drug
Lead sponsor: NeuroRx, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Birmingham, Alabama • Fort Lauderdale, Florida • Charlotte, North Carolina + 1 more

Conditions: Cancer Prevention
Interventions: Cancer control navigation (CNN), General referral (usual care); Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 1,554 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Patients Receiving Fractionated Stereotactic Radiotherapy, for Brain Tumors
Interventions: GTC frame, Thermoplastic facemask, Stereotactic radiation therapy; Device · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: Zidovudine, Acyclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 3
States / cities: Los Angeles, California • San Diego, California • Seattle, Washington

Conditions: Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Salivary Gland Carcinoma, Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary, Stage III Major Salivary Gland Carcinoma, Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage III Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma, Stage IVA Major Salivary Gland Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVB Major Salivary Gland Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVC Major Salivary Gland Carcinoma, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
Interventions: Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat; Other · Biological · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Specific Language Impairment
Interventions: Treatment (interactive book reading, dialogic reading, shared book reading); Behavioral
Lead sponsor: University of Kansas; Other
Eligibility: 5 Years to 6 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Lawrence, Kansas

Conditions: Body Temperature, Thermosensing, Temperature
Interventions: Zero-heat-flux thermometry; Device
Lead sponsor: 3M; Industry
Eligibility: Up to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 3 Years and older
Enrollment: 1,091 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cirrhosis, Periodontitis, Gingivitis
Interventions: Dental Cleaning; Procedure
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Parkinson's Disease
Interventions: Donepezil; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 30 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

Peer Support Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation

Whole Body Vibration Combined With L-citrulline Supplementation on Cardiovascular Function and Body Composition

Dosing Flexibility Study in Patients With Rheumatoid Arthritis

Computer-Based Comprehensive Geriatric Assessment in Oncology for Individuals 70 or Older With Gastrointestinal Malignancies

iCare HOME2 Clinical Trial

Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study

Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery

A Study of Olomorasib (LY3537982) in Healthy Participants

Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer Risk

Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)

Investigation of Pupillometry as Guide for Extubation Readiness in Anesthetized Children

Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia

Influenza Vaccination Digital Interventions for People Living With Diabetes

Sequential Therapy for the Treatment of Severe Bipolar Depression.

Increasing Breast, Cervical, and Colorectal Cancer Screening and HPV Vaccination Among Underserved Texans

Comparing Two Forms of Head Immobilization for Stereotactic Radiotherapy

A Study of Zidovudine Plus Acyclovir in HIV-Infected Patients

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

Accelerating Word Learning in Children With Language Impairment

Zero Heat Flux Thermometry System Comparison Trial

Genetic, Brain Structure, and Environmental Effects on ADHD

Oral Gut Liver Axis in Cirrhosis

Effects of Cholinergic Augmentation on Measures of Balance and Gait